Endovascular therapy for cerebral infarction due to Trousseau syndrome in a patient with non-small cell lung cancer

Kai, Yoshiro; Ohara, Hiroya; Matsuda, Masayuki; Shimizu, Hironori; Park, Hun Soo; Myouchin, Kaoru; Kikutsuji, Naoya; Hontsu, Shigeto; Yamauchi, Motoo; Yoshikawa, Masayuki; Muro, Shigeo

doi:10.1016/j.rmcr.2021.101531

Cited by 4 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Casementioning

confidence: 94%

“…To our best knowledge, there have been six case reports of EGFR-mutant NSCLC patients with CAIS (10)(11)(12)(13)(14)(15). Cancer-associated ischemic stroke preceded or coincided with the detection of lung cancer in three of these six patients (10,11,14). Two patients developed CAIS during TKI treatment: one patient developed symptoms two days after the start of the TKI (12), and the other one during interruption TKI due to adverse effects of the TKI (15).…”

Section: Casementioning

confidence: 97%

“…The PFS and OS of our two patients were 17 and 22 months for case 1 and 5 and 14 months for case 2, respectively. Among the above-mentioned six EGFR mutated NSCLC patients with CAIS, four cases of PFS were described in their reports, and median PFS of them was four months (2-10 months) (10,14,15). Overall survival was described in five patients, with their median OS being eight months (1-22 months) (10-12, 14, 15).…”

Section: Casementioning

confidence: 99%

“…There has been no established standard of therapy for CAIS; for many patients it is common to administer heparin at the time of onset, and after gradually tapering off heparin for periods ranging from several days to several months (10)(11)(12). Some patients first received thrombomodulin alfa or tissue plasminogen activator as initial treatment (13,14), followed by clopidogrel, a direct oral anticoagulant, as subsequent treatment (15).…”

Section: Casementioning

confidence: 99%

“…We herein report two EGFR-mutated patients with CAIS: concomitant diagnosis of lung cancer and CAIS in one patient, and metachronous diagnosis of CAIS during a dministration of cytotoxic anticancer drugs after development of EGFR-TKI resistance in another patient. CAIS in patients with EGFR-positive NSCLC has been reported to occur before, during, or after TKI therapy (10)(11)(12)(13)(14)(15). It is important to pay attention to the development of CAIS even in EGFR gene-positive patients who could be e xpected to have a long-term survival.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

EGFR Mutated Non-Small Cell Lung Cancer Complicated by Cancer Associated Ischemic Stroke

TAGUCHI,

KAWAKAMI,

HASEGAWA

et al. 2023

Maedica

View full text Add to dashboard Cite

We describe herein two patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) who developed cancer-associated ischemic stroke (CAIS), infarction caused by thromboembolism in the central nervous system. Case 1 was a 63-year-old man with Exon 19 deletion type EGFR mutated lung adenocarcinoma presenting with CAIS. Case 2 was a 71-year-old woman with Exon 21 L858R type EGFR mutated lung adenocarcinoma who developed CAIS during chemotherapy after EGFR-tyrosine kinase inhibitor (TKI) resistance. Although there was no recurrence of CAIS in these patients, anticancer therapy could be hampered by the comorbidity of CAIS. This can develop anytime from before clinical manifestations of NSCLC to the next treatment after EGFR-TKI resistance. The development of CAIS should be noted in patients with EGFR mutated NSCLC, who have a promising long-term prognosis. Anticancer and anticoagulant therapies as well as rehabilitation are important for patients who develop CAIS. Establishment of measurement tests to detect CAIS before onset is desired.

show abstract